Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.793
Peer-review started: December 20, 2023
First decision: January 17, 2024
Revised: January 18, 2024
Accepted: February 27, 2024
Article in press: February 27, 2024
Published online: April 15, 2024
This letter to the editor discusses the publication on gut microbiome supplementation as therapy for metabolic syndrome. Gut microbiome dysbiosis disrupts intestinal bacterial homeostasis and is related to chronic inflammation, insulin resistance, cardiovascular diseases, type 2 diabetes mellitus, and obesity. Previous research has found that increasing the abundance of beneficial microbiota in the gut modulates metabolic syndrome by reducing chronic inflammation and insulin resistance. Prebiotics, probiotics, synbiotics, and postbiotics are often used as supplements to increase the number of beneficial microbes and thus the produc
Core Tip: I am writing to express my appreciation for the enlightening study titled “Gut microbiome supplementation as therapy for metabolic syndrome” recently published in your esteemed journal. The findings presented in this research shed light on the pivotal role of the gut microbiome in modulating metabolic syndrome, emphasizing the potential therapeutic impact of supplementation. The paper delves into the diverse array of supplements, including probiotics, synbiotics and postbiotics, and their distinct effects on the gut microbiome and its association with metabolic syndrome. I believe that this study will further investigations, inspire clinical trials, and foster the development of targeted interventions to enhance metabolic health through the modulation of the gut microbiome. Our research group is also researching the role of the gut microbiota in chronic liver disease. This article will be of great help to our research.